Blueprint Medicines Corp - Company Profile

Powered by

All the data and insights you need on Blueprint Medicines Corp in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Blueprint Medicines Corp Strategy Report

  • Understand Blueprint Medicines Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Blueprint Medicines Corp: Overview

Select Item

Related keylists

Blueprint Medicines Corp (Blueprint Medicines) is a precision therapy company that invented medicines for the treatment of cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) for non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines also offers GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. The company is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discovery which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Blueprint Medicines Corp and make more informed decisions for your business Gain a 360-degree view of Blueprint Medicines Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 45 Sidney Street, Cambridge, Massachusetts, 02139
Website www.blueprintmedicines.com
Telephone 1 617 3747580
No of Employees 655
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange BPMC (NASD)
Revenue (2022) $249.4M 22.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 9.1% (2022 vs 2021)
Market Cap* $5.3B
Net Profit Margin (2022) XYZ 25.6% (2022 vs 2021)
* As of and is in US$
View Blueprint Medicines Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Blueprint Medicines Corp premium industry data and analytics

120+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Blueprint Medicines Corp’s relevant decision makers and contact details.

90+

Catalyst Calendar

Proactively evaluate Blueprint Medicines Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Clinical Trials

Determine Blueprint Medicines Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Pipeline Drugs

Identify which of Blueprint Medicines Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Marketed Drugs

Understand Blueprint Medicines Corp’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Blueprint Medicines Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline AYVAKIT
AYVAKIT (avapritinib) - Advanced Systemic Mastocytosis, Indolent SM GAVRETO
Elenestinib (BLU-263) (KIT)- Indolent SM
XYZ
XYZ
XYZ
Understand Blueprint Medicines Corp portfolio and identify potential areas for collaboration Understand Blueprint Medicines Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In January, the company and VantAI entered into an agreement to improve novel targeted protein degrader therapies.
2023 Regulatory Approval In December, the company secured approval from the European Commission for AYVAKYT for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms.
2023 Regulatory Approval In January, the company announced that FDA approved the company's supplemental new drug application for AYVAKIT (avapritinib) for the treatment of adults with indolent systemic mastocytosis.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Blueprint Medicines Corp Pfizer Inc Bayer AG Novartis AG AstraZeneca Plc
Headquarters United States of America United States of America Germany Switzerland United Kingdom
City Cambridge New York Leverkusen Basel Cambridge
State/Province Massachusetts New York Nordrhein-Westfalen - England
No. of Employees 655 88,000 99,723 76,057 89,900
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jeffrey W. Albers Chairman Executive Board 2022 51
Kate Haviland Director; President; Chief Executive Officer Executive Board 2022 47
Mike Landsittel Chief Financial Officer Senior Management 2019 51
Christina Rossi Chief Operating Officer Senior Management 2022 47
Debra Durso-Bumpus Chief People Officer Senior Management 2020 53
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Blueprint Medicines Corp key executives to enhance your sales strategy Gain insight into Blueprint Medicines Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward